Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) - Total Assets

Latest as of March 2026: CN¥6.82 Billion CNY ≈ $997.38 Million USD

Based on the latest financial reports, Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) holds total assets worth CN¥6.82 Billion CNY (≈ $997.38 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 688076 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.

Sinopep-Allsino Biopharmaceutical Co. Ltd. A - Total Assets Trend (2013–2025)

This chart illustrates how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's total assets have evolved over time, based on quarterly financial data. Check 688076 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.

Sinopep-Allsino Biopharmaceutical Co. Ltd. A - Asset Composition Analysis

Current Asset Composition (December 2025)

Sinopep-Allsino Biopharmaceutical Co. Ltd. A's total assets of CN¥6.82 Billion consist of 37.3% current assets and 62.7% non-current assets.

Asset Category	Amount (CNY)	% of Total Assets
Cash & Equivalents	CN¥0.00	13.6%
Accounts Receivable	CN¥500.68 Million	7.4%
Inventory	CN¥859.52 Million	12.8%
Property, Plant & Equipment	CN¥0.00	0.0%
Intangible Assets	CN¥453.57 Million	6.7%
Goodwill	CN¥156.34 Million	2.3%

Asset Composition Trend (2013–2025)

This chart illustrates how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Sinopep-Allsino Biopharmaceutical Co. Lt market capitalisation.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Sinopep-Allsino Biopharmaceutical Co. Ltd. A's current assets represent 37.3% of total assets in 2025, an increase from 7.6% in 2013.
Cash Position: Cash and equivalents constituted 13.6% of total assets in 2025, up from 5.8% in 2013.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, a decrease from 13.0% in 2013.
Asset Diversification: The largest asset category is inventory at 12.8% of total assets.

Sinopep-Allsino Biopharmaceutical Co. Ltd. A Competitors by Total Assets

Key competitors of Sinopep-Allsino Biopharmaceutical Co. Ltd. A based on total assets are shown below.

Company	Country	Total Assets
argenx NV ADR NASDAQ:ARGX	USA	$8.68 Billion
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	China	CN¥37.98 Billion
Tubize-Fin BR:TUB	Belgium	€1.93 Billion
Hebei Changshan Biochem Pharma SHE:300255	China	CN¥4.66 Billion
Metsera, Inc. Common Stock NASDAQ:MTSR	USA	$639.66 Million
Neuren Pharmaceuticals Ltd AU:NEU	Australia	AU$331.25 Million
Wuhan Hvsen Biotechnology Co Ltd SHE:300871	China	CN¥3.25 Billion
Shenzhen Weiguang Biological Products Co Ltd SHE:002880	China	CN¥3.67 Billion

Sinopep-Allsino Biopharmaceutical Co. Ltd. A - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	1.17	1.06	5.35
Quick Ratio	0.75	0.73	4.27
Cash Ratio	0.00	0.00	0.00
Working Capital	CN¥360.63 Million	CN¥116.44 Million	CN¥846.51 Million

Sinopep-Allsino Biopharmaceutical Co. Ltd. A - Advanced Valuation Insights

This section examines the relationship between Sinopep-Allsino Biopharmaceutical Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	3.26
Latest Market Cap to Assets Ratio	0.19
Asset Growth Rate (YoY)	32.7%
Total Assets	CN¥6.74 Billion
Market Capitalization	$1.27 Billion USD

Valuation Analysis

Below Book Valuation: The market values Sinopep-Allsino Biopharmaceutical Co. Ltd. A's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Sinopep-Allsino Biopharmaceutical Co. Ltd. A's assets grew by 32.7% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Sinopep-Allsino Biopharmaceutical Co. Ltd. A (2013–2025)

The table below shows the annual total assets of Sinopep-Allsino Biopharmaceutical Co. Ltd. A from 2013 to 2025.

Year	Total Assets	Change
2025-12-31	CN¥6.74 Billion ≈ $986.32 Million	+32.74%
2024-12-31	CN¥5.08 Billion ≈ $743.07 Million	+43.15%
2023-12-31	CN¥3.55 Billion ≈ $519.07 Million	+40.64%
2022-12-31	CN¥2.52 Billion ≈ $369.09 Million	+18.59%
2021-12-31	CN¥2.13 Billion ≈ $311.23 Million	+52.40%
2020-12-31	CN¥1.40 Billion ≈ $204.22 Million	+12.14%
2019-12-31	CN¥1.24 Billion ≈ $182.11 Million	+18.43%
2018-12-31	CN¥1.05 Billion ≈ $153.77 Million	+71.86%
2017-12-31	CN¥611.47 Million ≈ $89.48 Million	+281.90%
2016-12-31	CN¥160.11 Million ≈ $23.43 Million	-18.59%
2015-12-31	CN¥196.67 Million ≈ $28.78 Million	+29.75%
2014-12-31	CN¥151.58 Million ≈ $22.18 Million	-9.13%
2013-12-31	CN¥166.81 Million ≈ $24.41 Million	--

About Sinopep-Allsino Biopharmaceutical Co. Ltd. A

SHG:688076 China Biotechnology

Market Cap

$1.27 Billion

CN¥8.67 Billion CNY

Market Cap Rank

#8039 Global

#1923 in China

Share Price

CN¥27.43

Change (1 day)

+1.07%

52-Week Range

CN¥27.14 - CN¥49.31

All Time High

CN¥90.43